Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM Bristol Myers Squibb has announced compelling results from its pivotal Phase 3 SCOUT-HCM clinical trial, highlighting the potential of Camzyos (mavacamten) as a transformative…
Enveric Biosciences Announces Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Enveric Biosciences, a biotechnology company focused on developing next-generation neuroplastogenic small molecules for psychiatric and neurological disorders, has provided a comprehensive corporate update following the filing of…
Angelalign Technology Reports 2025 Results, Highlighting Clinical Excellence as a Key Driver of Global Expansion Angelalign Technology Inc. (6699.HK) has announced its financial results for the fiscal year 2025, reporting strong performance across both its domestic China market and international…
Alpha Cognition Inc. Announces Fiscal 2025 Financial Results and Operational Progress Update Alpha Cognition Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative disorders, has reported its financial results for the fourth quarter and full year ending…
WuXi Biologics Announces Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Infrastructure WuXi Biologics has reported strong financial and operational performance for 2025, marking a year of significant growth and strategic transformation. As a leading global Contract Research,…
Medpace Holdings, Inc. Schedules Release of First Quarter 2026 Financial Results for April 22, 2026 Medpace Holdings has announced the upcoming release of its financial results for the first quarter of 2026, providing investors and stakeholders with an opportunity to…
Celltrion Plans Cancellation of 9.11 Million Treasury Shares to Strengthen Shareholder Value Amid Market Volatility Celltrion has announced a significant corporate governance and capital management initiative aimed at strengthening shareholder value and reinforcing investor confidence during a period of heightened…
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results Silence Therapeutics plc, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full…
Verastem Oncology Reports Strong Progress in 2025 with Drug Launch, Pipeline Advances, and Financial Updates Verastem Oncology reported its financial results for the fourth quarter and full year ending December 31, 2025, highlighting strong early revenue from its recently approved therapy, continued…
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) Esperion and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema…
Delcath Systems Reports Publication of CHOPIN Clinical Trial Findings in The Lancet Oncology Delcath Systems, Inc. an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the…
Cryo-Cell International Sees Revenue Dip and Net Loss in Fiscal 2025 What does a year of financial downturn mean for the world’s first private cord blood bank? Cryo-Cell International, Inc. a pioneer in cord blood and cord tissue cryopreservation, has…